PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 92 filers reported holding PARATEK PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.94 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $190,000 | +8.0% | 44,000 | 0.0% | 0.00% | -20.0% |
| Q2 2019 | $176,000 | -25.4% | 44,000 | 0.0% | 0.01% | -16.7% |
| Q1 2019 | $236,000 | +4.4% | 44,000 | -0.1% | 0.01% | -33.3% |
| Q4 2018 | $226,000 | -47.1% | 44,023 | 0.0% | 0.01% | -18.2% |
| Q3 2018 | $427,000 | -4.5% | 44,023 | +0.4% | 0.01% | 0.0% |
| Q2 2018 | $447,000 | -14.0% | 43,830 | +9.6% | 0.01% | -31.2% |
| Q1 2018 | $520,000 | -17.1% | 40,000 | +14.3% | 0.02% | 0.0% |
| Q4 2017 | $627,000 | -28.7% | 35,000 | 0.0% | 0.02% | -51.5% |
| Q3 2017 | $879,000 | +82.4% | 35,000 | +75.0% | 0.03% | +65.0% |
| Q2 2017 | $482,000 | +149.7% | 20,000 | +100.0% | 0.02% | +150.0% |
| Q1 2017 | $193,000 | +25.3% | 10,000 | 0.0% | 0.01% | +14.3% |
| Q4 2016 | $154,000 | +1.3% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $152,000 | -20.0% | 10,000 | 0.0% | 0.01% | -46.2% |
| Q4 2015 | $190,000 | -33.3% | 10,000 | -33.3% | 0.01% | 0.0% |
| Q3 2015 | $285,000 | – | 15,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $36,172,000 | 26.83% |
| Abingworth LLP | 1,301,413 | $18,103,000 | 18.96% |
| Roumell Asset Management, LLC | 290,136 | $4,036,000 | 9.16% |
| Monashee Investment Management LLC | 100,000 | $1,391,000 | 2.19% |
| BVF INC/IL | 575,000 | $7,998,000 | 1.70% |
| Aisling Capital LLC | 482,680 | $6,714,000 | 1.59% |
| Opaleye Management Inc. | 146,700 | $2,041,000 | 1.36% |
| Broadfin Capital, LLC | 803,332 | $11,174,000 | 1.09% |
| GENERAL AMERICAN INVESTORS CO INC | 477,076 | $6,636,000 | 0.69% |
| Opus Point Partners Management, LLC | 37,665 | $524,000 | 0.51% |